Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION An FAERS cluster in a demographic the trials under-enrolled put disproportionate reporting signal workbook in front of clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Pharmacovigilance close is to drop a secondary from disproportionate reporting signal workbook, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after an FAERS cluster in a demographic the trials under-enrolled for clinical-development physician. 3. Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision to drop a secondary turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences Pharmacovigilance close, clinical-development physician must state the unresolved clinical or safety evidence requirement explicitly.